Gerard Evan

Gerard Evan
Born (1955-08-17) 17 August 1955 [1]
Alma mater St Peter's College, Oxford
King's College, Cambridge[1]
Known for Disease Models & Mechanisms
Awards Fellow of the Royal Society (2004)
FMedSci (1999)[2]
PhD (1982)
Scientific career
Fields Cancer[3][4][5][6][7][8]
Disease biology
Myc regulator gene[9]
p53 tumour suppressor[10]
Institutions University of Oxford
University of Cambridge
UCSF[1][11]
Cancer Research UK[12]
Ensemble Therapeutics
Thesis Monoclonal antibodies as reagents for the analysis of cell surfaces (1982)
Website www.bioc.cam.ac.uk/uto/evan
labmed.ucsf.edu/about/faculty/pathology-gevan.html

Gerard Ian Evan FRS, FMedSci (born 17 August 1955) is a British biologist and Sir William Dunn Professor of Biochemistry at the University of Cambridge.[11][13]

Education

Evan was educated at St Peter's College, Oxford and King’s College, Cambridge, where he was awarded his PhD in 1982 for research using Monoclonal antibodies.[1][14]

Research

Evan does research to the determine the molecular basis of cancer.[15][16][17][18][19][20][21][22]

Career

Prior to Cambridge, Evan was Gerson & Barbara Bass Bakar Distinguished Professor of Cancer Biology, at University of California, San Francisco. Evan is also a member of the Advisory Board, of Ensemble Therapeutics Corporation[23][24] and a founding editor of the journal Disease Models & Mechanisms.[7]

References

  1. 1 2 3 4 "EVAN, Prof. Gerard Ian". Who's Who 2013, A & C Black, an imprint of Bloomsbury Publishing plc, 2013; online edn, Oxford University Press. (subscription required)
  2. ↑ http://www.acmedsci.ac.uk/p59fid5303.html
  3. ↑ Finch, A. J.; Soucek, L.; Junttila, M. R.; Swigart, L. B.; Evan, G. I. (2009). "Acute Overexpression of Myc in Intestinal Epithelium Recapitulates Some but Not All the Changes Elicited by Wnt/ -Catenin Pathway Activation". Molecular and Cellular Biology. 29 (19): 5306–5315. doi:10.1128/MCB.01745-08. PMC 2747972. PMID 19635809.
  4. ↑ Garcia, D.; Warr, M. R.; Martins, C. P.; Brown Swigart, L.; Passegue, E.; Evan, G. I. (2011). "Validation of MdmX as a therapeutic target for reactivating p53 in tumors". Genes & Development. 25 (16): 1746–1757. doi:10.1101/gad.16722111. PMC 3165938. PMID 21852537.
  5. ↑ Murphy, D. J.; Junttila, M. R.; Pouyet, L.; Karnezis, A.; Shchors, K.; Bui, D. A.; Brown-Swigart, L.; Johnson, L.; Evan, G. I. (2008). "Distinct Thresholds Govern Myc's Biological Output in Vivo". Cancer Cell. 14 (6): 447–457. doi:10.1016/j.ccr.2008.10.018. PMC 2723751. PMID 19061836.
  6. ↑ Sodir, N. M.; Swigart, L. B.; Karnezis, A. N.; Hanahan, D.; Evan, G. I.; Soucek, L. (2011). "Endogenous Myc maintains the tumor microenvironment". Genes & Development. 25 (9): 907–916. doi:10.1101/gad.2038411. PMC 3084025. PMID 21478273.
  7. 1 2 Kain, K. (2008). "The future of cancer therapy: An interview with Gerard Evan". Disease Models and Mechanisms. 1 (2–3): 90–93. doi:10.1242/dmm.001396. PMC 2562192. PMID 19048069.
  8. ↑ Anon (2008). "Making the paper: Gerard Evan". Nature. 455 (7213): xiii. doi:10.1038/7213xiiia.
  9. ↑ Evan, G. (2012). "Taking a Back Door to Target Myc". Science. 335 (6066): 293–294. doi:10.1126/science.1217819. PMID 22267799.
  10. ↑ Junttila, Melissa R.; Evan, Gerard I. (2009). "P53 — a Jack of all trades but master of none". Nature Reviews Cancer. 9 (11): 821–829. doi:10.1038/nrc2728. PMID 19776747.
  11. 1 2 "UCSF Departments of Pathology and Laboratory Medicine | About | Faculty | Gerard I. Evan, PhD, FRS, FMedSci". Archived from the original on 17 June 2013.
  12. ↑ "Gerard Evan : Cancer Research UK". Archived from the original on 17 June 2013.
  13. ↑ List of publications from Microsoft Academic
  14. ↑ Evan, Gerard (1982). Monoclonal antibodies as reagents for the analysis of cell surfaces (PhD thesis). University of Cambridge.
  15. ↑ Christophorou, M. A.; Ringshausen, I.; Finch, A. J.; Swigart, L. B.; Evan, G. I. (2006). "The pathological response to DNA damage does not contribute to p53-mediated tumour suppression". Nature. 443 (7108): 214–217. doi:10.1038/nature05077. PMID 16957739.
  16. ↑ Junttila, M. R.; Karnezis, A. N.; Garcia, D.; Madriles, F.; Kortlever, R. M.; Rostker, F.; Brown Swigart, L.; Pham, D. M.; Seo, Y.; Evan, G. I.; Martins, C. P. (2010). "Selective activation of p53-mediated tumour suppression in high-grade tumours". Nature. 468 (7323): 567–571. doi:10.1038/nature09526. PMC 3011233. PMID 21107427.
  17. ↑ Soucek, L.; Whitfield, J.; Martins, C. P.; Finch, A. J.; Murphy, D. J.; Sodir, N. M.; Karnezis, A. N.; Swigart, L. B.; Nasi, S.; Evan, G. I. (2008). "Modelling Myc inhibition as a cancer therapy". Nature. 455 (7213): 679–683. doi:10.1038/nature07260. PMC 4485609. PMID 18716624.
  18. ↑ Evan, Gerard I.; Vousden, Karen H. (2001). "Proliferation, cell cycle and apoptosis in cancer". Nature. 411 (6835): 342–348. doi:10.1038/35077213. PMID 11357141.
  19. ↑ Hueber, A. O.; Zörnig, M.; Lyon, D.; Suda, T.; Nagata, S.; Evan, G. I. (1997). "Requirement for the CD95 receptor-ligand pathway in c-Myc-induced apoptosis". Science. 278 (5341): 1305–1309. doi:10.1126/science.278.5341.1305. PMID 9360929.
  20. ↑ Chittenden, T.; Harrington, E. A.; O'Connor, R.; Remington, C.; Lutz, R. J.; Evan, G. I.; Guild, B. C. (1995). "Induction of apoptosis by the Bcl-2 homologue Bak". Nature. 374 (6524): 733–736. doi:10.1038/374733a0. PMID 7715730.
  21. ↑ Fanidi, A.; Harrington, E. A.; Evan, G. I. (1992). "Cooperative interaction between c-myc and bcl-2 proto-oncogenes". Nature. 359 (6395): 554–556. doi:10.1038/359554a0. PMID 1406976.
  22. ↑ Amati, B.; Dalton, S.; Brooks, M. W.; Littlewood, T. D.; Evan, G. I.; Land, H. (1992). "Transcriptional activation by the human c-Myc oncoprotein in yeast requires interaction with Max". Nature. 359 (6394): 423–426. doi:10.1038/359423a0. PMID 1406955.
  23. ↑ http://investing.businessweek.com/research/stocks/private/person.asp?personId=38914899
  24. ↑ http://www.ensembletx.com/about/sab.html
Academic offices
Preceded by
Tom Blundell		 Sir William Dunn Professor of Biochemistry at the University of Cambridge
2009–present		 Incumbent
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.